Biophytis presented the potential of Ruvembri™ in the treatment of Duchenne Muscular Dystrophy

Biophytis presented the results of its recent clinical trials with Ruvembri™ at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held from 3 to 6 March 2024 in Orlando, USA.

Administered orally, Ruvembri™ activates the MAS receptor, stimulating respiratory and motor functions. The results of the SARA-INT (phase 2) and COVA (phase 3) clinical trials demonstrated the efficacy and safety of Ruvembri™, respectively in sarcopenic patients and those suffering from severe forms of COVID-19. The data collected on these two vulnerable populations confirm the potential of Ruvembri™ in the treatment of patients suffering from Duchenne Muscular Dystrophy (DMD).

Ruvembri™ has already obtained the orphan drug designation in Europe and the USA for this indication, which will accelerate clinical development and market authorization procedures. Biophytis aims to start in 2024 a phase 1-2 clinical trial in non-ambulatory DMD patients suffering from respiratory failure.

Stanislas Veillet, CEO of Biophytis, stated: “Duchenne Muscular Dystrophy is a severe orphan condition which generally appears between the ages of 2 and 5 years by progressive muscle weakness, loss of walking capacity and later cardio-respiratory difficulties responsible for the early death of young adults. Despite some recent advances and the great hope generated by gene therapy, there is no satisfactory treatment today and the medical need is still substantial, particularly for non-ambulatory patients. The treatment of DMD, the world’s most common neuromuscular disease, represents a market of USD 2.5 billion, which is expected to grow rapidly to USD 4.3 billion by 2029.”

The infographic presented at the conference can be viewed by clicking on this link.